Rosenblatt cuts Lumentum target to $900 from $1,300
Rosenblatt Securities lowered its price target for Lumentum Holdings to $900 from $1,300.
Related stories
Syra Health Reports Record Q3 Revenue and Gross Margin
Syra Health reported third-quarter 2026 revenue of $2.56 million, up 52% year over year, with a record 46.3% gross margin. It reported net income of $344,610 versus a loss a year e
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Rhythm Pharmaceuticals Shares Fall 8.7% After Q3 Net Loss
Rhythm Pharmaceuticals reported a net loss for the third quarter, and its shares fell 8.7%.
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
UL Solutions Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Sysco Reports First-Quarter Sales, Earnings Growth; Revises Sales Outlook
Sysco reported fiscal first-quarter sales of $21.7 billion, up 2.8%, and net earnings of $526 million, up 10.5% year over year. Adjusted EPS rose 3.5% to $1.19 and adjusted EBITDA
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Waters Corp Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
EBS: trading halted on NYSE — additional information requested (last $6.46)
NYSE halted trading in EBS (additional information requested). Last price $6.46.
L impact | EQUITY | Nov 03, 2026, 02:33 PM UTC